NCT03294694 2025-05-31
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
3 trialsNCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown